Creo Medical (CREO.L)

Executive Summary

Creo Medical is a UK-based medical device company pioneering Advanced Energy technology for minimally invasive endoscopic surgery. Its proprietary Kamaptive platform uniquely combines microwave and bipolar radiofrequency energy, enabling precise cutting, coagulation, and ablation in a single device. The company targets high-growth therapeutic endoscopy markets including gastroenterology, urology, pulmonology, and surgery, aiming to improve patient outcomes and procedural efficiency. With three commercial products and a growing IP portfolio, Creo is positioned to capture market share in the rapidly expanding field of minimally invasive surgery. The company is publicly listed on the London Stock Exchange (CREO.L) with a current valuation of approximately £51.8 million, reflecting its early commercialization stage and significant upside potential as it scales adoption. Creo's strategy focuses on expanding its product indications, building direct sales channels in key geographies, and forging strategic partnerships with leading endoscopic solution providers. The company's Kamaptive technology has demonstrated clinical advantages in terms of reduced procedure time, lower complication rates, and enhanced precision compared to conventional devices. With a strong pipeline of next-generation instruments and ongoing clinical studies, Creo is well-positioned to drive further penetration in existing markets and enter new therapeutic areas. Despite the competitive landscape, Creo's differentiated technology and regulatory progress in the US and Europe provide a solid foundation for growth. Key risks include slower-than-expected commercial adoption and the need for additional capital to fund expansion.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for Creo's Kamaptive system in new urology indication70% success
• Q2 2026Strategic distribution partnership with a major global endoscopy firm (e.g., Olympus or Medtronic)60% success
• Q4 2026Launch of next-generation Speedboat UltraBlade device for advanced endoscopic submucosal dissection80% success